JP2023061927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023061927A5 JP2023061927A5 JP2023002879A JP2023002879A JP2023061927A5 JP 2023061927 A5 JP2023061927 A5 JP 2023061927A5 JP 2023002879 A JP2023002879 A JP 2023002879A JP 2023002879 A JP2023002879 A JP 2023002879A JP 2023061927 A5 JP2023061927 A5 JP 2023061927A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- positions
- conditions
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 8
- 230000007935 neutral effect Effects 0.000 claims 6
- 230000004962 physiological condition Effects 0.000 claims 6
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 5
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 5
- 230000002378 acidificating effect Effects 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 230000006044 T cell activation Effects 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 claims 2
- 229920002971 Heparan sulfate Polymers 0.000 claims 2
- 108090000054 Syndecan-2 Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004236 Ponceau SX Substances 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000012506 imaged capillary isoelectric focusing Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024179648A JP2025023919A (ja) | 2017-03-14 | 2024-10-15 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471196P | 2017-03-14 | 2017-03-14 | |
| US62/471,196 | 2017-03-14 | ||
| US201862636746P | 2018-02-28 | 2018-02-28 | |
| US62/636,746 | 2018-02-28 | ||
| PCT/US2018/022230 WO2018169993A1 (en) | 2017-03-14 | 2018-03-13 | Antibodies binding to vista at acidic ph |
| JP2019549389A JP7211961B2 (ja) | 2017-03-14 | 2018-03-13 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549389A Division JP7211961B2 (ja) | 2017-03-14 | 2018-03-13 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024179648A Division JP2025023919A (ja) | 2017-03-14 | 2024-10-15 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023061927A JP2023061927A (ja) | 2023-05-02 |
| JP2023061927A5 true JP2023061927A5 (enExample) | 2023-06-05 |
| JP7573659B2 JP7573659B2 (ja) | 2024-10-25 |
Family
ID=63522565
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549389A Active JP7211961B2 (ja) | 2017-03-14 | 2018-03-13 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
| JP2023002879A Active JP7573659B2 (ja) | 2017-03-14 | 2023-01-12 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
| JP2024179648A Pending JP2025023919A (ja) | 2017-03-14 | 2024-10-15 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549389A Active JP7211961B2 (ja) | 2017-03-14 | 2018-03-13 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024179648A Pending JP2025023919A (ja) | 2017-03-14 | 2024-10-15 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11603406B2 (enExample) |
| EP (1) | EP3595720A4 (enExample) |
| JP (3) | JP7211961B2 (enExample) |
| KR (2) | KR20240151866A (enExample) |
| CN (2) | CN110740749B (enExample) |
| AU (2) | AU2018236218B2 (enExample) |
| BR (1) | BR112019019108A2 (enExample) |
| CA (1) | CA3054067A1 (enExample) |
| CL (2) | CL2019002610A1 (enExample) |
| CO (1) | CO2019010943A2 (enExample) |
| IL (2) | IL326895A (enExample) |
| MX (1) | MX2024003316A (enExample) |
| MY (1) | MY200609A (enExample) |
| PE (2) | PE20250933A1 (enExample) |
| SG (1) | SG11201907848YA (enExample) |
| TW (3) | TWI825010B (enExample) |
| WO (1) | WO2018169993A1 (enExample) |
| ZA (1) | ZA201905525B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4793360A2 (en) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| KR20210074395A (ko) | 2011-11-30 | 2021-06-21 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| EP4624490A3 (en) | 2012-02-09 | 2025-11-05 | Chugai Seiyaku Kabushiki Kaisha | Modified fc region of antibody |
| CA2865158C (en) | 2012-02-24 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| ES2812208T3 (es) * | 2013-03-14 | 2021-03-16 | Bristol Myers Squibb Co | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| CN114773469B (zh) | 2015-02-05 | 2025-12-19 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE |
| CN109071631B (zh) | 2016-03-14 | 2023-07-14 | 奥斯陆大学 | 具有改变的FcRn结合的工程化免疫球蛋白 |
| CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| KR20250159733A (ko) | 2017-01-11 | 2025-11-11 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| PE20250933A1 (es) * | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| US11220550B2 (en) | 2017-05-25 | 2022-01-11 | Bristol-Myers Squibb Company | Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity |
| SG11202008593PA (en) | 2018-03-21 | 2020-10-29 | Five Prime Therapeutics Inc | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
| US20190300610A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| GB201814562D0 (en) | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
| AU2019301120A1 (en) | 2018-07-11 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
| KR20250024129A (ko) * | 2018-07-20 | 2025-02-18 | 피에르 파브르 메디카먼트 | Vista의 수용체 |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| CA3149719A1 (en) * | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| BR112022012010A2 (pt) | 2019-12-18 | 2022-08-30 | Hoffmann La Roche | Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune |
| BR112023016533A2 (pt) * | 2021-02-18 | 2023-11-21 | Kineta Inc | Anticorpos antivista e usos dos mesmos |
| EP4373848A2 (en) | 2021-07-22 | 2024-05-29 | University of Dundee | Therapeutic muteins |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997913A (en) | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
| US5605821A (en) | 1989-03-08 | 1997-02-25 | Board Of Regents Of The University Of Oklahoma | Expression control sequences of the P-selectin gene |
| DK0714912T3 (da) | 1990-07-17 | 2003-02-03 | Univ Oklahoma | Funktionelt aktive selektin-deriverede peptider og ligander for GMP-140 |
| US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
| US6277975B1 (en) | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
| AU677261B2 (en) | 1992-10-23 | 1997-04-17 | Genetics Institute, Llc | Novel P-selectin ligand protein |
| EP0668907A1 (en) | 1992-11-16 | 1995-08-30 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for p-selectin and methods of use thereof |
| WO1995030001A2 (en) | 1994-04-28 | 1995-11-09 | Genetics Institute, Inc. | Novel p-selectin ligand protein |
| DE69630307T2 (de) | 1995-08-03 | 2004-07-15 | The Board Of Regents Of The University Of Oklahoma, Norman | O-glycaninhibitoren von selectinvermittelten entzüngen |
| WO1997009068A2 (en) | 1995-09-01 | 1997-03-13 | University Of Washington | Interactive molecular conjugates |
| EP1040117A4 (en) | 1997-12-18 | 2005-03-09 | Human Genome Sciences Inc | 110 HUMAN SECRETED PROTEINS |
| CA2331386A1 (en) | 1998-06-26 | 2000-01-06 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
| NZ510464A (en) | 1998-09-01 | 2004-05-28 | Genentech Inc | Further pro polypeptides and sequences thereof |
| AU2883700A (en) | 1999-06-23 | 2001-01-09 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1200582A2 (en) | 1999-07-08 | 2002-05-02 | Sagami Chemical Research Center | Human proteins having hydrophobic domains and dnas encoding these proteins |
| PL362227A1 (en) | 2000-03-24 | 2004-10-18 | Genetic Institute, Llc | A novel p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor |
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| AU2003256266A1 (en) | 2002-06-12 | 2003-12-31 | Genencor International, Inc. | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
| US20040152105A1 (en) | 2002-09-06 | 2004-08-05 | Cytos Biotechnology Ag. | Immune modulatory compounds and methods |
| US20050260711A1 (en) * | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
| MY148646A (en) | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
| BRPI0510561A (pt) | 2004-05-11 | 2007-11-20 | Abgenomics Corp | epìtopos que induzem morte de célula t |
| PL1781682T3 (pl) | 2004-06-24 | 2013-08-30 | Mayo Found Medical Education & Res | Polipeptyd kostymulujący B7-H5 |
| US8231872B2 (en) | 2005-04-25 | 2012-07-31 | The Trustees Of Dartmouth College | Regulatory T cell mediator proteins and uses thereof |
| WO2006116181A2 (en) | 2005-04-25 | 2006-11-02 | Trustees Of Dartmouth College | Regulatory t cell mediator proteins and uses thereof |
| WO2007033959A2 (en) | 2005-09-19 | 2007-03-29 | Vib Vzw | Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas |
| WO2007067984A2 (en) | 2005-12-09 | 2007-06-14 | Wyeth | Neutralizing antibodies against primate psgl-1 and uses therefor |
| US7655778B2 (en) | 2006-02-28 | 2010-02-02 | Curonix Co., Ltd. | SISP-1, a novel p53 target gene and use thereof |
| US20100129368A9 (en) * | 2006-10-11 | 2010-05-27 | Ablynx N.V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof |
| US8119130B2 (en) | 2007-07-25 | 2012-02-21 | Medimmune Limited | Targeted binding agents directed to KDR and uses thereof—035 |
| WO2009100110A1 (en) | 2008-02-05 | 2009-08-13 | Medarex, Inc. | Alpha 5 - beta 1 antibodies and their uses |
| AU2009221915A1 (en) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 12 binding proteins |
| AU2009246166B2 (en) | 2008-05-15 | 2014-09-18 | Tetherex Pharmaceuticals Corporation | Anti-PSGL-1 antibodies and methods of identification and use |
| JP2012515556A (ja) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| MX355507B (es) * | 2009-03-09 | 2018-04-19 | Bioatla Llc | Proteinas mirac. |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| CN103119054B (zh) | 2010-03-26 | 2017-01-18 | 达特茅斯大学理事会 | Vista调节性t细胞介体蛋白、vista结合剂及其用途 |
| JP6042801B2 (ja) | 2010-04-27 | 2016-12-14 | ロシュ グリクアート アーゲー | ｍＴＯＲインヒビターとのアフコシル化ＣＤ２０抗体の併用療法 |
| KR20130096731A (ko) * | 2010-09-08 | 2013-08-30 | 할로자임, 아이엔씨 | 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법 |
| EP2718325A4 (en) | 2011-06-13 | 2015-03-11 | ABGENOMICS COöPERATIEF U A | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF |
| CA2853412C (en) * | 2011-10-28 | 2021-05-04 | University Of Zurich | Tdp-43 specific binding molecules |
| JP6181066B2 (ja) | 2011-11-28 | 2017-08-16 | ショー，グレイ，ディー． | 新規な増強型セレクチンアンタゴニスト |
| CA2866612C (en) | 2012-03-08 | 2018-01-16 | Halozyme, Inc. | Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof |
| CN104619722B (zh) | 2012-06-22 | 2022-10-04 | 达特茅斯大学理事会 | 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途 |
| US9890215B2 (en) * | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| CA2884704C (en) | 2012-09-07 | 2023-04-04 | Randolph J. Noelle | Vista modulators for diagnosis and treatment of cancer |
| SMT201900242T1 (it) | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
| AU2014268298B2 (en) | 2013-05-24 | 2019-01-17 | Medlmmune, Llc | Anti-B7-H5 antibodies and their uses |
| EP3003390B1 (en) | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| EA201690912A1 (ru) | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| US10273301B2 (en) * | 2013-12-24 | 2019-04-30 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| EP3094346B1 (en) | 2014-01-14 | 2019-12-11 | The Trustees Of Dartmouth College | Vista antagonist and methods of use |
| RU2550262C1 (ru) | 2014-02-28 | 2015-05-10 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело |
| WO2015187359A1 (en) | 2014-06-04 | 2015-12-10 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for targeting a pathway |
| JP6997619B2 (ja) | 2014-06-11 | 2022-01-17 | キャシー・エイ・グリーン | 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用 |
| EP4079324A1 (en) | 2014-07-08 | 2022-10-26 | Sanford-Burnham Medical Research Institute | Psgl-1 modulators and uses thereof |
| JOP20150008B1 (ar) * | 2014-11-26 | 2021-08-17 | Janssen Pharmaceutica Nv | أجسام مضادة ل vista وأجزاء منها |
| MX2017007136A (es) | 2014-12-05 | 2017-12-04 | Immunext Inc | Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8. |
| KR102693806B1 (ko) | 2014-12-11 | 2024-08-09 | 피에르 파브르 메디카먼트 | 항-c10orf54 항체들 및 그들의 용도들 |
| AR103268A1 (es) | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| AU2016271111B2 (en) * | 2015-05-29 | 2022-04-28 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| EP3722314A1 (en) | 2015-06-24 | 2020-10-14 | Janssen Pharmaceutica NV | Anti-vista antibodies and fragments |
| CA3003399A1 (en) | 2015-11-02 | 2017-05-11 | Bioatla, Llc | Conditionally active polypeptides |
| WO2017120534A1 (en) | 2016-01-08 | 2017-07-13 | Bioalliance C.V. | Tetravalent anti-psgl-1 antibodies and uses thereof |
| US10899836B2 (en) | 2016-02-12 | 2021-01-26 | Janssen Pharmaceutica Nv | Method of identifying anti-VISTA antibodies |
| WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
| PE20190115A1 (es) | 2016-04-15 | 2019-01-16 | Immunext Inc | Anticuerpos vista antihumanos y su uso |
| WO2017181109A1 (en) | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
| US11649285B2 (en) | 2016-08-03 | 2023-05-16 | Bio-Techne Corporation | Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy |
| WO2018047143A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
| KR20250159733A (ko) | 2017-01-11 | 2025-11-11 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
| PE20250933A1 (es) | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| WO2018195772A1 (en) | 2017-04-25 | 2018-11-01 | Sun Yat-Sen University | Pd-1h as target in treatement of asthma |
| CA3067835A1 (en) | 2017-06-22 | 2018-12-27 | Apexigen, Inc. | Anti-vista antibodies and methods of use |
| CA3079652C (en) | 2017-10-20 | 2022-07-19 | Pharmabcine Inc. | Anti-vista antibody and use thereof |
| EP3706798A1 (en) | 2017-11-06 | 2020-09-16 | Aurigene Discovery Technologies Limited | Conjoint therapies for immunomodulation |
| US20210085785A1 (en) | 2018-02-23 | 2021-03-25 | Truebinding, Inc. | Treating cancer by blocking the interaction of vista and its binding partner |
| SG11202008593PA (en) * | 2018-03-21 | 2020-10-29 | Five Prime Therapeutics Inc | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| WO2019185163A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Vista antigen-binding molecules |
| AU2019301120A1 (en) | 2018-07-11 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
| CN109878421B (zh) | 2019-03-13 | 2020-11-03 | 浙江吉利控股集团有限公司 | 车辆坡道装置及汽车 |
| CN110563843A (zh) | 2019-07-25 | 2019-12-13 | 钟小泉 | 一种靶向人vista蛋白的单克隆抗体 |
-
2018
- 2018-03-13 PE PE2025000182A patent/PE20250933A1/es unknown
- 2018-03-13 JP JP2019549389A patent/JP7211961B2/ja active Active
- 2018-03-13 MY MYPI2019004903A patent/MY200609A/en unknown
- 2018-03-13 PE PE2019001859A patent/PE20191708A1/es unknown
- 2018-03-13 CN CN201880031212.2A patent/CN110740749B/zh active Active
- 2018-03-13 CN CN202410878453.8A patent/CN118894937A/zh active Pending
- 2018-03-13 KR KR1020247033048A patent/KR20240151866A/ko active Pending
- 2018-03-13 AU AU2018236218A patent/AU2018236218B2/en active Active
- 2018-03-13 SG SG11201907848YA patent/SG11201907848YA/en unknown
- 2018-03-13 WO PCT/US2018/022230 patent/WO2018169993A1/en not_active Ceased
- 2018-03-13 KR KR1020197029923A patent/KR102715540B1/ko active Active
- 2018-03-13 US US16/493,712 patent/US11603406B2/en active Active
- 2018-03-13 BR BR112019019108-9A patent/BR112019019108A2/pt active Search and Examination
- 2018-03-13 CA CA3054067A patent/CA3054067A1/en active Pending
- 2018-03-13 IL IL326895A patent/IL326895A/en unknown
- 2018-03-13 EP EP18767615.0A patent/EP3595720A4/en active Pending
- 2018-03-14 TW TW107108715A patent/TWI825010B/zh active
- 2018-03-14 TW TW114122239A patent/TW202615470A/zh unknown
- 2018-03-14 TW TW112143312A patent/TWI890190B/zh active
-
2019
- 2019-08-21 ZA ZA2019/05525A patent/ZA201905525B/en unknown
- 2019-09-10 IL IL269240A patent/IL269240B2/en unknown
- 2019-09-12 CL CL2019002610A patent/CL2019002610A1/es unknown
- 2019-09-12 MX MX2024003316A patent/MX2024003316A/es unknown
- 2019-10-02 CO CONC2019/0010943A patent/CO2019010943A2/es unknown
-
2021
- 2021-10-21 CL CL2021002769A patent/CL2021002769A1/es unknown
-
2023
- 2023-01-12 JP JP2023002879A patent/JP7573659B2/ja active Active
- 2023-02-01 US US18/162,991 patent/US12195535B2/en active Active
-
2024
- 2024-10-15 JP JP2024179648A patent/JP2025023919A/ja active Pending
- 2024-11-25 US US18/958,201 patent/US20250206822A1/en active Pending
-
2025
- 2025-05-28 AU AU2025203967A patent/AU2025203967A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020509756A5 (enExample) | ||
| CN104774266B (zh) | 白介素-13结合蛋白 | |
| TWI508745B (zh) | ＴＮＦ－α結合蛋白 | |
| JP5918275B2 (ja) | 変形性関節症及び疼痛の治療 | |
| JP2022513420A5 (enExample) | ||
| RU2770209C2 (ru) | Терапевтические антитела против лиганда cd40 | |
| CN119735681A (zh) | 优化的抗tl1a抗体 | |
| JP2020504087A (ja) | ４−１ｂｂ結合タンパク質及びその使用 | |
| JP2008542278A5 (enExample) | ||
| KR20110110349A (ko) | Ｉｌ-1 결합 단백질 | |
| JP2022546454A5 (enExample) | ||
| RU2011101969A (ru) | Антитела к человеческому интерлейкину-20 | |
| JP2016517277A (ja) | ＴＮＦαに対して指向された二重特異的結合タンパク質 | |
| CN105358175B (zh) | 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法 | |
| JP2010532764A5 (enExample) | ||
| KR20110040886A (ko) | 프로스타글란딘 ｅ2 결합 단백질 및 이의 용도 | |
| JP2023505492A5 (enExample) | ||
| JP2010501164A5 (enExample) | ||
| CA3156096C (en) | Pd1 and vegfr2 dual-binding agents | |
| JP2021533204A5 (enExample) | ||
| JP2025507595A5 (enExample) | ||
| JP2022513421A5 (enExample) | ||
| CN106565840A (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| JP2022502024A5 (enExample) | ||
| JP2015518368A5 (enExample) |